Aminophylline

CHEMBL1370561 Phase 4 Aprobado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
420.4 g/mol
LogP
Phase
4

A combination of theophylline and ethylenediamine that relaxes the smooth muscle of the bronchi and pulmonary blood vessels, used to treat asthma and COPD by opening narrowed airways and stimulating breathing. It also has mild diuretic effects and can treat apnea in premature infants by stimulating the respiratory center in the brain.

Peso molecular

420,4300 g/mol

TPSA

191,00 Ų

Áreas terapéuticas

Mecanismo de acción

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN

InChI

InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2

Molecular Formula

C16H24N10O4

HBD / HBA

4 / 8

Enlaces Rotables

1

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A combination of theophylline and ethylenediamine that relaxes the smooth muscle of the bronchi and pulmonary blood vessels, used to treat asthma and COPD by opening narrowed airways and stimulating breathing. It also has mild diuretic effects and can treat apnea in premature infants by stimulating the respiratory center in the brain.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Aminophylline is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1370561. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9433. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.